{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:16:36Z","timestamp":1792714596631,"version":"4.5.0"},"reference-count":33,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,3,14]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hemophilia is a bleeding disorder that afflicts about 1 in 5000 males. Treatment relies upon replacement of the deficient factor, and response to treatment both in clinical research and practice is based upon subjective parameters such as pain and joint mobility. Existing laboratory assays quantify the amount of factor in plasma, which is useful diagnostically and prognostically. However, these assays are limited in their ability to fully evaluate the patient\u2019s clot-forming capability. Newer assays, known as global assays, provide a far more detailed view of thrombin generation and clot formation and have been studied in hemophilia for about 10 years. They have the potential to offer a more objective measure of both the hemophilic phenotype as well as the response to treatment. In particular, in patients who develop inhibitors to deficient clotting factors and in whom bypassing agents are required for hemostasis, these assays offer the opportunity to determine the laboratory response to these interventions where traditional coagulation assays cannot. In this article we review the existing literature and discuss several controversial issues surrounding the assays. Last, a vision of future clinical uses of these assays is briefly described.<\/jats:p>","DOI":"10.1182\/blood-2012-08-378935","type":"journal-article","created":{"date-parts":[[2013,1,15]],"date-time":"2013-01-15T04:52:32Z","timestamp":1358225552000},"page":"1944-1950","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":145,"title":["Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives"],"prefix":"10.1182","volume":"121","author":[{"given":"Guy","family":"Young","sequence":"first","affiliation":[{"name":"Children\u2019s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benny","family":"S\u00f8rensen","sequence":"additional","affiliation":[{"name":"Haemostasis Research Unit, Center for Haemostasis and Thrombosis, Guy\u2019s and St Thomas\u2019 Foundation Trust, London, United Kingdom;"},{"name":"King\u2019s College London School of Medicine, London, United Kingdom;"},{"name":"Centre for Haemophilia and Thrombosis, Aarhus University Hospital, Skejby, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesim","family":"Dargaud","sequence":"additional","affiliation":[{"name":"Unite d\u2019Hemostase Clinique, Hopital Edouard Herriot Lyon, University of Lyon 1, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Negrier","sequence":"additional","affiliation":[{"name":"Unite d\u2019Hemostase Clinique, Hopital Edouard Herriot Lyon, University of Lyon 1, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Brummel-Ziedins","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, University of Vermont, Colchester, VT; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel S.","family":"Key","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of North Carolina-Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7","key":"2019111809125182200_B1","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/MBC.0b013e32832c8803","article-title":"Challenges of defining reliable clinical surrogate end points in haemophilia trials: a critical review.","volume":"20","author":"Amby","year":"2009","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"4","key":"2019111809125182200_B2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/00000441-193510000-00009","article-title":"A study of the coagulation defect in hemophilia and in jaundice.","volume":"190","author":"Quick","year":"1935","journal-title":"Am J Med Sci"},{"issue":"1","key":"2019111809125182200_B3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood.V100.1.148","article-title":"Thrombin functions during tissue factor-induced blood coagulation.","volume":"100","author":"Brummel","year":"2002","journal-title":"Blood"},{"issue":"4","key":"2019111809125182200_B4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2796.1994.tb00815.x","article-title":"A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs.","volume":"236","author":"Aledort","year":"1994","journal-title":"J Intern Med"},{"issue":"1","key":"2019111809125182200_B5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma.","volume":"33","author":"Hemker","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"2019111809125182200_B6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/9781444318555.ch40","article-title":"Global laboratory assays in hemophilia.","volume-title":"Textbook of Hemophilia","author":"Sorensen","year":"2010","edition":"2nd ed"},{"issue":"3","key":"2019111809125182200_B7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1160\/TH04-10-0706","article-title":"Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B.","volume":"93","author":"Dargaud","year":"2005","journal-title":"Thromb Haemost"},{"issue":"4","key":"2019111809125182200_B8","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1538-7836.2010.03767.x","article-title":"Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile.","volume":"8","author":"Santagostino","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2019111809125182200_B9","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1538-7836.2007.02861.x","article-title":"Mild hemophilia A with factor VIII assay discrepancy: potential utility of thrombin generation assays.","volume":"6","author":"Trossaert","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2019111809125182200_B10","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1365-2516.2005.01141.x","article-title":"Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision.","volume":"11","author":"Dargaud","year":"2005","journal-title":"Haemophilia"},{"issue":"25","key":"2019111809125182200_B11","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1182\/blood-2010-06-291906","article-title":"Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery.","volume":"116","author":"Dargaud","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111809125182200_B12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2516.2008.01931.x","article-title":"Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors.","volume":"15","author":"Berntorp","year":"2009","journal-title":"Haemophilia"},{"issue":"2 Suppl 1","key":"2019111809125182200_B13","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1053\/j.seminhematol.2008.03.002","article-title":"Monitoring inhibitor patients with the right assays.","volume":"45","author":"Barrowcliffe","year":"2008","journal-title":"Semin Hematol"},{"issue":"4","key":"2019111809125182200_B14","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2516.2005.01107.x","article-title":"Thrombin generation and phenotypic correlation in haemophilia A.","volume":"11","author":"Beltr\u00e1n-Miranda","year":"2005","journal-title":"Haemophilia"},{"issue":"37-38","key":"2019111809125182200_B15","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/BF01697545","article-title":"Blutgerinnungsstudien mit der Thrombelastographie; einem neuen Untersuchungs verfahren.","volume":"26","author":"Hartert","year":"1948","journal-title":"Klin Wochenschr"},{"issue":"suppl 1","key":"2019111809125182200_B16","first-page":"90","article-title":"A comparison of the technical principle of the roTEG coagulation analyzer and conventional thrombelastographic systems.","volume":"72","author":"Calatzis","year":"1996","journal-title":"Ann Hematol"},{"issue":"5","key":"2019111809125182200_B17","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00001721-200107000-00001","article-title":"Thrombelastography.","volume":"12","author":"Salooja","year":"2001","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"3","key":"2019111809125182200_B18","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1046\/j.1538-7836.2003.00075.x","article-title":"Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation.","volume":"1","author":"S\u00f8rensen","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2019111809125182200_B19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1538-7836.2004.00528.x","article-title":"Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa.","volume":"2","author":"Sorensen","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2019111809125182200_B20","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2516.2006.01319.x","article-title":"Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography.","volume":"12","author":"Young","year":"2006","journal-title":"Haemophilia"},{"issue":"5","key":"2019111809125182200_B21","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/j.1365-2516.2009.01994.x","article-title":"Thrombin generation and bleeding in haemophilia A.","volume":"15","author":"Brummel-Ziedins","year":"2009","journal-title":"Haemophilia"},{"issue":"3","key":"2019111809125182200_B22","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1538-7836.2010.04171.x","article-title":"Factor XIII combined with recombinant factor VIIa: a new means of treating severe hemophilia A.","volume":"9","author":"Rea","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"12","key":"2019111809125182200_B23","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1111\/j.1538-7836.2007.02755.x","article-title":"Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe haemophilia A. J.","volume":"5","author":"Hvas","year":"2007","journal-title":"Thromb Haemost"},{"issue":"2","key":"2019111809125182200_B24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1365-2141.2008.07063.x","article-title":"Thromboelastography in children with coagulation factor deficiencies.","volume":"142","author":"Chitlur","year":"2008","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111809125182200_B25","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2141.2007.06534.x","article-title":"Factor VIIa analogue (V158D\/E296V\/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A.","volume":"137","author":"S\u00f8rensen","year":"2007","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111809125182200_B26","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1160\/TH10-01-0019","article-title":"Platelet infusion supports recombinant factor VIIa in a patient with severe haemophilia A and inhibitor\u2014clinical outcome and laboratory observations.","volume":"103","author":"S\u00f8rensen","year":"2010","journal-title":"Thromb Haemost"},{"issue":"6","key":"2019111809125182200_B27","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.thromres.2012.07.017","article-title":"Evaluation of a standardized protocol for thrombin generation measurement using the calibrated automated thrombogram: an international multicentre study.","volume":"130","author":"Dargaud","year":"2012","journal-title":"Thromb Res"},{"issue":"2","key":"2019111809125182200_B28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1055\/s-0029-1220322","article-title":"Internal quality control and external quality assurance of platelet function tests.","volume":"35","author":"Favaloro","year":"2009","journal-title":"Semin Thromb Hemost"},{"issue":"8","key":"2019111809125182200_B29","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1111\/j.1538-7836.2006.02000.x","article-title":"Immunologic quantitation of tissue factors.","volume":"4","author":"Parhami-Seren","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2019111809125182200_B30","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/MBC.0b013e3283001cdc","article-title":"Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicenter trial.","volume":"19","author":"Young","year":"2008","journal-title":"Blood Coag Fibrin."},{"issue":"3","key":"2019111809125182200_B31","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1365-2516.2009.02165.x","article-title":"Comparison of kaolin and tissue factor activated thromboelastography in haemophilia.","volume":"16","author":"Young","year":"2010","journal-title":"Haemophilia"},{"issue":"2","key":"2019111809125182200_B32","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.thromres.2010.05.008","article-title":"Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven) therapy in haemophilia A patients.","volume":"126","author":"Viuff","year":"2010","journal-title":"Thromb Res"},{"issue":"2","key":"2019111809125182200_B33","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2516.2011.02638.x","article-title":"The influence of prophylactic factor VIII in severe haemophilia A.","volume":"18","author":"Gissel","year":"2012","journal-title":"Haemophilia"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/11\/1944\/1363960\/1944.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/11\/1944\/1363960\/1944.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T18:21:37Z","timestamp":1714846897000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/121\/11\/1944\/31067\/Thrombin-generation-and-whole-blood-viscoelastic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,14]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,3,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-08-378935","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,14]]}}}